Important Safety Information
RITUXAN Initial Treatment Plus CVP: Controlling Follicular non-Hodgkin’s Lymphoma for Longer
RITUXAN® is indicated for the treatment of patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy.
RITUXAN® can be used along with CVP chemotherapy as a treatment for follicular (indolent) NHL. And because they work to control this type of NHL in different ways, RITUXAN and chemotherapy may work very well together. What we mean by control is lower risk of progression, relapse, or death.
In a clinical study, RITUXAN plus CVP chemotherapy significantly shrunk tumors or stopped them from getting worse in some patients. And it kept them that way for longer. In fact, control was 71% longer (extended the length of time NHL was in control from 1.4 years to 2.4 years on average [with an 18-month median follow up]) than in people who received just CVP chemotherapy.
Important Safety Information:
- RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
- RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
- The most common side effects of RITUXAN seen in patients with non-Hodgkin’s lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
- Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor
How RITUXAN is given
For initial treatment of follicular NHL with RITUXAN plus CVP chemotherapy, you may receive a RITUXAN infusion:
- On day 1 of the CVP chemotherapy cycle
- For up to 8 infusions
Visit the Infusion Day Resource Center to learn more and to prepare for your infusion.
“One of the things that helped me when I was going through the chemo and the RITUXAN is that the nurses were just wonderful, and they put me more at ease. They didn't deny that there was a problem but they said, ‘We can treat you’.” —Terry, RITUXAN patient
This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.
Indications and Important Safety Information
RITUXAN® (Rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
People with serious infections should not receive RITUXAN.
Important Safety Information:
- RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
- RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
- The most common side effects of RITUXAN seen in patients with non-Hodgkin’s lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
- Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor
Please see full Prescribing Information, including Medication Guide.
